VTGN
VistaGen Therapeutics Inc
0.2462$
-0.4%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -85.1% | -100.0% | – | – | – | -100.0% | – | – | +226.2% | +1.8% | -120.5% | – | -54.3% | +161.1% | |
| – | – | – | – | – | -32.7% | -28.5% | -100.0% | – | +21,290.7% | -99.3% | +13.0% | +13.0% | – | – | -37.5% | +11.4% | +11.8% | – | |
| – | – | – | – | – | -85.1% | -100.0% | – | – | – | -100.0% | – | – | – | +1.8% | -120.5% | – | -54.3% | +161.1% | |
| – | – | – | – | – | -36.3% | -27.7% | -1.9% | +61.6% | +32.4% | +49.2% | +120.3% | -22.1% | -10.5% | +196.9% | +25.3% | -54.9% | +96.7% | +39.6% | |
| – | +241.8% | +31.7% | -61.0% | +51,819.0% | -18.2% | -28.5% | +66.6% | +227.8% | -57.8% | +9.7% | +15.5% | -11.2% | +7.5% | +47.3% | +40.3% | -4.1% | +21.5% | +7.8% | |
| – | +242.5% | +34.1% | -59.3% | +115,992.1% | -32.7% | -28.1% | +32.8% | +167.3% | -35.6% | +23.5% | +72.8% | -19.0% | -4.3% | +157.0% | +20.8% | -42.3% | +65.6% | +30.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -47.0% | +55.6% | +195.6% | -83.2% | -99.4% | +78.0% | -10.1% | +87.5% | -13.3% | +1,684.6% | -90.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +0.0% | +0.0% | +5,233.3% | +131.3% | -27.0% | -11.1% | -4.2% | +4.3% | +0.0% | +8.3% | +0.0% | +0.0% | +30.8% | +73.5% | -32.2% | +75.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.